Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

著者: Gıancarlo Comı, Ludwig Kappos, Krzysztof Selmaj, Amit Bar‐Or, Douglas L. Arnold, Lawrence Steinman, Hans‐Peter Hartung, Xavier Montalbán, Eva Havrdová, Bruce Cree, James K. Sheffield, Neil Minton, Kartik Raghupathi, Ning Ding, Jeffrey A. Cohen - The Lancet 2019 被引用: 286